EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Unveiling mechanisms underlying kidney function changes during sex hormone therapy

Sarah A van Eeghen, Laura Pyle, Phoom Narongkiatikhun, Ye Ji Choi, Wassim Obeid, Chirag R Parikh, Taryn G Vosters, Irene Gm van Valkengoed, Merle M Krebber, Daan J Touw, Martin den Heijer, Petter Bjornstad und 2 weitere

Journal of Clinical Investigation · 01.05.2025 · 135 (9)

DOI: 10.1172/jci190850 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Journal of Clinical Investigation, online erschienen am 25.03.2025. Verfasst von Sarah A van Eeghen und 13 weiteren Autor:innen. Beteiligte Einrichtung: Center of Expertise on Gender Dysphoria, Department of Internal Medicine, Amsterdam UMC, Location VU University, Amsterdam, Netherlands. Hauptthemen laut MEDLINE: Androgen Antagonists, Estradiol, Glomerular Filtration Rate, Kidney. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, NCATS NIH HHS, Colorado Clinical and Translational Sciences Institute MicroGrant and CO-Pilot award.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND Men with chronic kidney disease (CKD) experience faster kidney function decline than women. Studies in individuals undergoing sex hormone therapy suggest a role for sex hormones, as estimated glomerular filtration rate (eGFR) increases with feminizing therapy and decreases with masculinizing therapy. However, effects on measured GFR (mGFR), glomerular and tubular function, and involved molecular mechanisms remain unexplored. METHODS This prospective, observational study included individuals initiating feminizing (estradiol and antiandrogens; n = 23) or masculinizing (testosterone; n = 21) therapy. Baseline and 3-month assessments included mGFR (iohexol clearance), kidney perfusion (para-aminohippuric acid clearance), tubular injury biomarkers, and plasma proteomics. RESULTS During feminizing therapy, mGFR and kidney perfusion increased (+3.6% and +9.1%, respectively; P < 0.05) without increased glomerular pressure. Tubular injury biomarkers, including urine neutrophil gelatinase-associated lipocalin, epidermal growth factor (EGF), monocyte chemoattractant protein-1, and chitinase 3-like protein 1 (YKL-40), decreased significantly (–53%, –42%, –45%, and –58%, respectively). During masculinizing therapy, mGFR and kidney perfusion remained unchanged, but urine YKL-40 and plasma tumor necrosis factor receptor 1 (TNFR-1) increased (+134% and +8%, respectively; P < 0.05). Proteomic analysis revealed differential expression of 49 proteins during feminizing and 356 proteins during masculinizing therapy. Many kidney-protective proteins were positively associated with estradiol and negatively associated with testosterone, including proteins involved in endothelial function (SFRP4, SOD3), inflammation reduction (TSG-6), and maintaining kidney tissue structure (agrin). CONCLUSION Sex hormones influence kidney physiology, with estradiol showing protective effects on glomerular and tubular function, while testosterone predominantly exerts opposing effects. These findings emphasize the role of sex hormones in sexual dimorphism observed in kidney function and physiology and suggest new approaches for sex-specific precision medicine. TRIAL REGISTRATION Dutch Trial Register (ID: NL9517); ClinicalTrials.gov (ID: NCT04482920).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Androgen AntagonistsEstradiolGlomerular Filtration RateKidneyRenal Insufficiency, ChronicTestosteroneAdultAgedFemaleHumansMaleMiddle AgedBiomarkersProspective Studies

Stichwörter der Autor:innen

Chronic kidney diseaseEndocrinologyNephrologySex hormones

Substanzen

Androgen AntagonistsBiomarkersEstradiolTestosterone

Autor:innen und Institutionen

  • Center of Expertise on Gender Dysphoria, Department of Internal Medicine, Amsterdam UMC, Location VU University, Amsterdam, Netherlands.
  • Amsterdam Gastroenterology Endocrinology Metabolism Research Institute, Amsterdam, Netherlands.
  • Department of Internal Medicine, Endocrinology and Metabolism, Amsterdam UMC, Location VU University, Amsterdam, Netherlands.
  • Department of Medicine, Division of Endocrinology, Metabolism and Nutrition, University of Washington School of Medicine, Seattle, Washington, USA.
  • Department of Pediatrics, Section of Endocrinology, University of Colorado School of Medicine, Aurora, Colorado, USA.
  • Division of Nephrology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.

Förderung

  • NHLBI NIH HHS
  • NCATS NIH HHS
  • Colorado Clinical and Translational Sciences Institute MicroGrant and CO-Pilot award

Zitieren

APA

van Eeghen, S. A., Pyle, L., Narongkiatikhun, P., Choi, Y. J., Obeid, W., Parikh, C. R., Vosters, T. G., van Valkengoed, I. G., Krebber, M. M., Touw, D. J., den Heijer, M., Bjornstad, P., van Raalte, D. H., & Nokoff, N. J. (2025). Unveiling mechanisms underlying kidney function changes during sex hormone therapy. Journal of Clinical Investigation, 135(9). https://doi.org/10.1172/jci190850

Vancouver

van Eeghen SA, Pyle L, Narongkiatikhun P, Choi YJ, Obeid W, Parikh CR, et al. Unveiling mechanisms underlying kidney function changes during sex hormone therapy. Journal of Clinical Investigation. 2025;135(9). doi:10.1172/jci190850

BibTeX
@article{vanEeghen2025,
  author = {van Eeghen, Sarah A and Pyle, Laura and Narongkiatikhun, Phoom and Choi, Ye Ji and Obeid, Wassim and Parikh, Chirag R and Vosters, Taryn G and van Valkengoed, Irene Gm and Krebber, Merle M and Touw, Daan J and den Heijer, Martin and Bjornstad, Petter and van Raalte, Daniël H and Nokoff, Natalie J},
  title = {Unveiling mechanisms underlying kidney function changes during sex hormone therapy},
  journal = {Journal of Clinical Investigation},
  year = {2025},
  volume = {135},
  number = {9},
  doi = {10.1172/jci190850}
}
Kostenlos starten →